To Explore the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Multiple Doses of HRS-7535 in Obese Subjects
Latest Information Update: 20 Apr 2025
At a glance
- Drugs HRS-7535 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Shandong Suncadia Medicine
Most Recent Events
- 09 Apr 2025 Status changed to active, no longer recruiting.
- 08 Oct 2024 New trial record